Arovella Therapeutics Ltd has released a press release.
Rights Issue Closes Significantly Oversubscribed
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Prospectus For Renounceable Pro Rata Offer
- Rights Issue To Raise Up To $3.44 Million
- Product Development Market Update
- ArTiMist Regulatory Update
Later from Arovella Therapeutics
- Supplementary Prospectus
- European Anagrelide Cancer Patent
- ZolpiMist Clinical Results Published
- ArTiMist Appeal Lodged With TGA
- Manaing Director and CEO Resignation
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics